Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego · 2021
Multiple endocrine neoplasia type 1 - a case report.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pasyechko Nadiya Vasylivna, Naumova Liudmyla Valeriivna, Burak Andrii Yevhenovych, Kulchinska Veronika Mykolaiivna, Krytskyy Taras Igorovych
Аннотация
UNLABELLED: Multiple endocrine neoplasia type 1 is a rare hereditary disease with an autosomal dominant type of inheritance characterized by high penetrance and the presence of hyperplasia and neoplasia in at least two different endocrine organs. The most often synchronously or consistently developing tumors are in the thyroid glands, the gastrointestinal tract and the adenohypophysis.
A CASE STUDY: A patient 41-year-old with multiple endocrine neoplasia type 1 was treated with radiolabeled somatostatin analogues as a new promising treatment for patients with inoperable or metastatic neuroendocrine tumors. The disease started with persistently recurrent prolactinoma, which was characterized by resistance not only to therapeutic but also to surgical treatment. Diagnostics methods used in this case were: laboratory - determination of the concentration of prolactin, vasoactive intestinal peptide, calcitonin, vitamin D3 (25-OH) D, parathormone, calcium, aldosterone, and ultrasound, CT, PET/CT.
CONCLUSIONS: Treatment with radiolabeled somatostatin analogues is a new promising treatment for patients with inoperable or metastatic neuroendocrine tumors. The difficulty of diagnosis of patients with combined pathology is that by fixing on one disease, you can miss the beginning of the other diseases. In this particular case, by concentrating on a tumor of the pancreas, it was possible to omit the recurrence of prolactinoma.
A CASE STUDY: A patient 41-year-old with multiple endocrine neoplasia type 1 was treated with radiolabeled somatostatin analogues as a new promising treatment for patients with inoperable or metastatic neuroendocrine tumors. The disease started with persistently recurrent prolactinoma, which was characterized by resistance not only to therapeutic but also to surgical treatment. Diagnostics methods used in this case were: laboratory - determination of the concentration of prolactin, vasoactive intestinal peptide, calcitonin, vitamin D3 (25-OH) D, parathormone, calcium, aldosterone, and ultrasound, CT, PET/CT.
CONCLUSIONS: Treatment with radiolabeled somatostatin analogues is a new promising treatment for patients with inoperable or metastatic neuroendocrine tumors. The difficulty of diagnosis of patients with combined pathology is that by fixing on one disease, you can miss the beginning of the other diseases. In this particular case, by concentrating on a tumor of the pancreas, it was possible to omit the recurrence of prolactinoma.